1
Clinical Trials associated with HS-10182晚期实体瘤受试者口服HS-10182的耐受性及药代动力学I期临床研究
[Translation] A Phase I Clinical Study on the Tolerability and Pharmacokinetics of Oral HS-10182 in Subjects with Advanced Solid Tumors
主要目的:确定HS-10182口服给药用于实体瘤的剂量限制性毒性(DLT)及最大耐受剂量(MTD)以及确定治疗晚期非小细胞肺癌的II期临床研究推荐剂量。 次要目的:1)确定HS-10182的药代动力学特征;2)确定HS-10182的安全性和耐受性;3)观察HS-10182治疗晚期非小细胞肺癌的有效性。
[Translation] The primary objective is to determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of oral HS-10182 for solid tumors and to determine the recommended dose for Phase II clinical studies in the treatment of advanced non-small cell lung cancer. Secondary objectives are: 1) to determine the pharmacokinetic characteristics of HS-10182; 2) to determine the safety and tolerability of HS-10182; 3) to observe the effectiveness of HS-10182 in the treatment of advanced non-small cell lung cancer.
100 Clinical Results associated with HS-10182
100 Translational Medicine associated with HS-10182
100 Patents (Medical) associated with HS-10182
100 Deals associated with HS-10182